Article
The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Dec 2001
Spurdle A B, Hopper J L, Chen X, Dite G S, McCredie M R, Giles G G, Venter D J, Southey M C, Purdie D M, Chenevix-Trench G
Abstract excerpt
The enzyme 5alpha-reductase type II (SRD5A2) converts testosterone to its more active form 5alpha-dihydroxytestosterone. The 3' untranslated region of the gene contains a (TA)(n) length polymorphism. The (TA)(9) allele has been reported to be associated with higher serum prostate-specific antigen levels in breast tumors and lower risk of relapse in breast cancer patients and more recently has also been reported...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.